A trial of IMRT to treat bone and soft tissue sarcoma (IMRiS)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Bone cancer
Ewing sarcoma
Soft tissue sarcoma




Phase 2

IMRT is a type of radiotherapy called intensity modulated radiotherapy, doctors want to see if it is a useful treatment for sarcoma and reduces side effects. Cancer Research UK supports this trial. 

More about this trial

Doctors might give radiotherapy 

  • before surgery to shrink the cancer before removing it
  • after surgery to reduce the risk of the cancer coming back
  • to treat the cancer if it can’t be removed because of its position in the body

Intensity modulated radiotherapy (IMRT) matches the radiotherapy beams to the shape of the cancer. This reduces the amount of radiotherapy to the healthy tissue surrounding the cancer. This should lead to fewer side effects. 

Some hospitals have used IMRT to treat bone and soft tissue sarcoma. But it hasn’t been properly tested to show if there is a benefit from treating these cancers with IMRT. 

The aims of this trial are 

  • to see if IMRT reduces side effects, particularly long term effects
  • to see if people with sarcoma are able to have the best dose of radiotherapy without causing damage to surrounding tissue

Who can enter

The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

You may be able to join this trial if you are in one of the following situations. You have

And you 

  • Are to have radiotherapy as part of your treatment
  • Are well enough to be up and about for at least half the day (performance status 0, 1 or 2
  • Are willing to use reliable contraception during treatment and for 3 months afterwards if you or your partner could become pregnant
  • Are at least 16 years old

You cannot join this trial if any of these apply. You

  • Have a type of sarcoma called paediatric alveolar or embryonal rhabdomyosarcoma
  • Are able to have proton beam radiotherapy if this is felt to be best for your tumour
  • Have already had radiotherapy to the area where your cancer is
  • Are having chemotherapy with radiotherapy (chemoradiation)
  • Have, or have had, another cancer
  • Are pregnant

Trial design

This is a phase 2 trial. The researchers need 188 people to join. 

Everyone will have intensity modulated radiotherapy (IMRT). Before you start IMRT you have a session to plan your radiotherapy.

You have IMRT once a day Monday to Friday for 5 to 7 weeks. How long depends on what type of sarcoma you have. 

Hospital visits

You see the doctor to have some tests before taking part. These tests include

During radiotherapy you see the doctor or nurse every week to see how you are. 

You then see the doctor 

  • Every month for 3 months
  • Every 3 months up to 3 years 

Depending on the type of sarcoma you have another 1 or 2 scans after finishing radiotherapy.

Side effects

The most common side effects of radiotherapy are

We have information on the side effects of radiotherapy.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Beatrice Seddon

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
University College London (UCL)

Other information

This is Cancer Research UK trial number CRUK/14/015. 

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

Currently rated: 5 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think